我們已在上線！進一步了解

Biohaven

BHVN

市值 US$16.3億

10.78 USD

-0.65

5.69%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

10.82

+0.04

0.37%

1天

-5.69%

5天

-9.49%

1個月

-10.32%

3個月

-23.92%

6個月

7.69%

今年迄今

-0.55%

1年

-34.59%

5年

50.98%

10年

50.98%

關於： Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

員工： 274

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 30%

中性 45%

負面 25%

Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement

Biohaven Ltd. (NYSE:BHVN) entered into a licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd.

Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states, led by BHV-1300 and including certain next-generation follow-on IgG degraders. Biohaven will receive up to $100 million in near-term payments, including $80 million upfront and eligible to receive another $20 million upon a milestone achievement anticipated within a year, and royalties of approximately twenty percent on net sales by Ono in the licensed territory.

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), a leading international forum for early-phase oncology drug development. First-in-class FGFR3 ADC: BHV-1530 is a first-in-class potential FGFR3-directed antibody-drug conjugate incorporating Biohaven's proprietary TopoIx payload, that has shown early clinical activity with a differentiated and tolerable safety profile.

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)

Biohaven shares gave up nearly 15% in a single session on September 10, 2026 following the FDA's partial clinical hold on new-patient enrollment in the BHV-7000/opakalim epilepsy trials NEW YORK, Sept. 11, 2026 /PRNewswire/ -- Biohaven Ltd (NYSE: BHVN) dropped $2.21, or about 14.73%, on September 10, 2026 after the Company disclosed that the FDA placed a partial clinical hold on new-patient enrollment in the Company's BHV-7000/opakalim epilepsy trials.

Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)

Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.

Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.

Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.

FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program

Biohaven Ltd. (NYSE:BHVN) on Thursday announced a partial clinical hold issued by the U.S. Food and Drug Administration (FDA) on new patient enrollment for its BHV-7000 program, while maintaining timelines for its lead pivotal study in refractory focal epilepsy.

FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program

Investors Business Daily

Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback

Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment due to safety concerns.

Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback

US FDA pauses new enrollment in Biohaven's epilepsy drug trials

Biohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enrollment in trials of its experimental epilepsy drug after rodent findings, sending its ‌shares down more than 13% in premarket trading.

US FDA pauses new enrollment in Biohaven's epilepsy drug trials

The Motley Fool

Why Biohaven Stock Was Rocking the Market This Week

Its partner is South Korean peer SK Biopharmaceuticals. It also secured a victory in a lawsuit.

Why Biohaven Stock Was Rocking the Market This Week

Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And More

Biohaven Ltd. maintains a Buy rating, driven by pivotal trial progress in protein degraders and a key licensing deal for its Kv7 platform with SK Biopharmaceuticals. BHVN-1300's phase 3 for Graves' disease is underway; BHV-1400's phase 3 for IgA nephropathy is set to start in H2 2026. Opakalim [BHV-7000] for refractory focal epilepsy is fully enrolled in phase 2/3, with topline data expected in H2 2026 and a $350M upfront SK Biopharmaceuticals deal secured.

Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And More

查看新聞排名

價格圖表採用Lightweight Charts™實作